IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.03

Index: ASX300 | ALL-ORDS

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.235 17 Apr 2025	0.010 OPEN $0.24	4.44% HIGH $0.25	1,242,353 LOW $0.23

TARGET

$0.70

197.9% upside

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY23 Actual	FY24 Actual	FY25 Forecast	FY26 Forecast
EPS (cps)	xxx	- 3.6	- 5.3	xxx
DPS (cps)	xxx	0.0	0.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	N/A	xxx
Dividend Yield	xxx	N/A	0.0%	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2019	2020	2021	2022	2023	2024
EPS Basic	xxx	xxx	xxx	xxx	xxx	-3.6
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	0.0 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	13.0
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-34.8 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-26.21 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-26.02 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-24.48 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-26.21 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-30.66 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-34.9 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	1 M
Total Debt	xxx	xxx	xxx	xxx	xxx	2 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	0 M
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	182 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	2.26

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Negative
Growth
Slowing

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Capex	xxx	xxx	xxx	xxx	xxx	0.9 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	-
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	2 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	48 M
Research & Development	xxx	xxx	xxx	xxx	xxx	31 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Bell Potter	18/11/2024	1	Speculative Buy	$0.70	197.87%	Bell Potter highlights a strong update from the Phase I Insight-003 trial, evaluating Eftilagimod alpha (Efti) in combination with Keytruda and chemotherapy for first-line non-small cell lung cancer (1L NSCLC) patients. The trial reported a median overall survival of 32.9 months for the first 21 patients, surpassing the 22 months observed in the historical Keytruda and chemotherapy Phase III trial (Keynote-189), explain the analysts. Bell Potter maintains a Speculative Buy rating and a target price of $0.70. FORECAST Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.30 cents. Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.60 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Bell Potter

18/11/2024

Speculative Buy

$0.70

197.87%

Bell Potter highlights a strong update from the Phase I Insight-003 trial, evaluating Eftilagimod alpha (Efti) in combination with Keytruda and chemotherapy for first-line non-small cell lung cancer (1L NSCLC) patients.

The trial reported a median overall survival of 32.9 months for the first 21 patients, surpassing the 22 months observed in the historical Keytruda and chemotherapy Phase III trial (Keynote-189), explain the analysts.

Bell Potter maintains a Speculative Buy rating and a target price of $0.70.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.30 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.60 cents.

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Canaccord Genuity	10/03/2025	1	Buy	$0.95	304.26%	Canaccord Genuity notes Immutep's 1H25 result was in line with expectations, with the company ending December with $159m cash and short-investments. This is sufficient to fund efti through the futility analysis of phase 3 expected in later 2025/early 2026, the broker suggests. The broker slightly raised estimates for R&D spending in FY25 and FY26 as TACTI-004 prepared to ramp up. Target price of 95c and Buy rating are unchanged. The broker expects a read from the TACTI-003 Cohort B data soon, noting its own analysis suggests a median overall survival of 15-19.5 months (previously 13.5-19.5 months). FORECAST Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.00 cents. Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.00 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Canaccord Genuity

10/03/2025

Buy

$0.95

304.26%

Canaccord Genuity notes Immutep's 1H25 result was in line with expectations, with the company ending December with $159m cash and short-investments.

This is sufficient to fund efti through the futility analysis of phase 3 expected in later 2025/early 2026, the broker suggests.

The broker slightly raised estimates for R&D spending in FY25 and FY26 as TACTI-004 prepared to ramp up. Target price of 95c and Buy rating are unchanged.

The broker expects a read from the TACTI-003 Cohort B data soon, noting its own analysis suggests a median overall survival of 15-19.5 months (previously 13.5-19.5 months).

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.00 cents.

Access Extra Coverage Research History >

IMM STOCK CHART

FNArena News on IMM

1	Australian Broker Call Extra Edition – Mar 10, 2025 Mar 10 2025 - Daily Market Reports

2	Australian Broker Call Extra Edition – Jan 29, 2025 Jan 29 2025 - Daily Market Reports

3	Australian Broker Call Extra Edition – Dec 16, 2024 Dec 16 2024 - Daily Market Reports

4	Australian Broker Call Extra Edition – Nov 19, 2024 Nov 19 2024 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 18, 2024 Sep 18 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

2	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

3	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

4	Dr Boreham’s Crucible: Aroa Biosurgery Jul 29 2024 - Small Caps

5	CSL Shares Breaking Free Jul 23 2024 - Technicals

6	Dr Boreham’s Crucible: SDI Jul 19 2024 - Small Caps

7	‘Defensive’ Pharmaceutical Wholesalers In Focus Jul 18 2024 - Australia

8	Twists And Turns Of Telix And Australian Biotech Jul 10 2024 - Small Caps

9	Dr Boreham’s Crucible: Radiopharm Theranostics Jul 03 2024 - Small Caps

10	Dr Boreham’s Crucible: Island Therapeutics Jun 17 2024 - Small Caps

Dividend Yield Today On Last Actual Payout :	0.00
Estimated Dividend Growth (Average Of Past Three Years)	%
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

1	Australian Broker Call Extra Edition – Mar 10, 2025 Mar 10 2025 - Daily Market Reports

2	Australian Broker Call Extra Edition – Jan 29, 2025 Jan 29 2025 - Daily Market Reports

3	Australian Broker Call Extra Edition – Dec 16, 2024 Dec 16 2024 - Daily Market Reports

4	Australian Broker Call Extra Edition – Nov 19, 2024 Nov 19 2024 - Daily Market Reports

5	Australian Broker Call Extra Edition – Sep 18, 2024 Sep 18 2024 - Daily Market Reports

Get 2 Weeks free trial

Sign Up

Member Login

IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart